Dr. Evan Wood, Numinus Chief Medical Officer, today announced the appointment of Dr. Devon Christie, MD CCFP RTC IFMCP, to the position of Medical Director at Numinus Wellness Inc. — another key step in the Company’s evolution as a leader in the advancement of psychedelic therapies, treatment and research.
“We are embarking on an exciting journey at Numinus,” said Dr. Wood. “We are working with health authorities, regulators and Colleges to advance research and protocol development to explore the application of psychedelic assisted psychotherapies in safe, controlled therapeutic environments. Devon will play a key role in the Company in helping to design and implement our patient-focused model for when we are able to put these therapies in place.”
Dr. Christie, a clinical instructor with the UBC Department of Medicine, is also a family physician with a focused practice in Multidisciplinary Pain Management. She is a Registered Therapeutic Counsellor emphasizing Relational Somatic Therapy for trauma resolution and she is also trained to deliver both MDMA-assisted psychotherapy for PTSD (MAPS USA) and ketamine-assisted psychotherapy, in a research setting. She is a recognized speaker and expert on the potential for incorporating psychedelic assisted therapies in an improved health care model for the future.
“As a medical doctor, I have always been interested in non-traditional approaches to therapy and treatment,” Dr. Christie said. “My unique and diverse clinical background, combined with rich personal experience helps me better understand and synthesize healing across disciplines — something Numinus is on a mission to achieve.”
In her role as Numinus’s Medical Director, she will lead a working group and advisory team for the purpose of protocol development and establishing a standard of excellence and professionalism in the safe and ethical delivery of Numinus’s new therapies; provide input on the organizational structure and lead the hiring of key clinical staff and contractors to establish the clinical team for the safe delivery of Numinus’ therapies (when psychedelic therapies are approved for use by regulators); and, as plans are developed to establish Numinus clinical sites, assist in the planning and establishment of physical infrastructure and clinic procedures required for delivering Numinus’ services.
Numinus is a Vancouver-based health care company helping to support the universal desire to heal and be well. Through its wholly-owned subsidiary Salvation Botanicals, Numinus has a Health Canada cannabis testing licence that allows the company to test and analyze cannabis products from licensed producers.